Yarrow Bioscience (YARW) Income from Discontinued Operations (2021 - 2026)

Yarrow Bioscience (YARW) has reported Income from Discontinued Operations for 6 consecutive years, with -$108000.0 the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Income from Discontinued Operations fell 1250.0% year-over-year to -$108000.0; the trailing twelve-month figure through Jun 2026 stood at -$124000.0 (down 416.67% YoY), and the FY2025 full-year result was $253000.0, up 1037.04% from the prior year.
• Income from Discontinued Operations retreated to -$108000.0 in Q2 2026 per YARW's latest filing, from -$8000.0 in the prior quarter.
• Across five years, Income from Discontinued Operations topped out at $13.4 million in Q1 2022 and bottomed at -$2.2 million in Q4 2022.
• Historically, Income from Discontinued Operations has averaged $714642.9 across 5 years, with a median of -$15500.0 in 2023.
• The sharpest annual moves came in 2022 and 2026: Income from Discontinued Operations soared 238.14% in 2022, then slumped 1250.0% in 2026.
• Over 5 years, Income from Discontinued Operations stood at -$2.2 million in 2022, then surged by 98.35% to -$36000.0 in 2023, then soared by 77.78% to -$8000.0 in 2024, then changed by 0.0% to -$8000.0 in 2025, then plunged by 1250.0% to -$108000.0 in 2026.
• According to Business Quant data, Income from Discontinued Operations over the past three periods registered -$108000.0, -$8000.0, and -$8000.0 for Q2 2026, Q2 2025, and Q1 2025 respectively.